Dexterra reports earnings after the market closes on November 4. Analysts expect C$0.26 per share and revenue of C$305.52 million for the quarter ended September 30, 2026. Its recent record is mixed: the company beat EPS estimates in two of its last four comparable quarters.
Dexterra Group Inc. (TSX: DXT) provides commercial services, and this report will show whether its recent growth continued into the fall. The EPS consensus has slipped from C$0.27 a month ago, with all three recorded revisions moving lower. Dexterra has beaten estimates in two of its last four comparable quarters, so its track record is a reason to watch the results—not to assume another beat.
Recent earnings trend
Dexterra Group Inc
DXT.TO
DXT.TO
Dexterra Group Inc
WealthAwesomeMarket cap
$1.15B
P/E
27.1x
Div. yield
2.24%
Div. / share
$0.40
52W high
$19.27
52W low
$9.95
1W change
+7.68%
Beta
0.50
Analyst Price Targets
Based on analyst covering DXT · as of Oct 21, 2026
Wall Street analysts forecast DXT stock price to rise 4.5% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$19.94
+4.5% Upside
Previously C$19.81 on Oct 15, 2026
Current Price
C$19.07
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on DXT's historical volatility
30-Day Vol
35.4%
Annualized
90-Day Vol
29.9%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$22.80
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$20.24 | C$17.91 – C$22.87 |
| 60 trading days | C$21.48 | C$18.07 – C$25.54 |
| 90 trading days | C$22.80 | C$18.45 – C$28.18 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 2 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 2 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-04 | — | 0.2600 | — |
| 2026-06-30 | 2026-08-04 | 0.2000 | 0.1800 | +11.1% |
| 2026-03-31 | 2026-05-06 | 0.1900 | 0.1600 | +18.8% |
| 2025-12-31 | 2026-03-03 | 0.1200 | 0.1800 | -33.3% |
| 2025-09-30 | 2025-11-04 | 0.2100 | 0.2100 | +0.0% |
| 2025-06-30 | 2025-08-05 | 0.1900 | 0.1900 | +0.0% |
Investor takeaway: The November 4 report will show whether Dexterra delivered the expected year-over-year growth and maintained its operating momentum. Analysts expect EPS to rise 21.4% from C$0.21 a year ago and revenue to grow 8.6%. The EPS estimate ranges from C$0.24 to C$0.27 and is based on two analysts; four analysts contribute to the revenue consensus. With so few estimates, consensus is a reference point, not a precise forecast. Compare the reported results with expectations and find more company information on the DXT stock page.
C$0.26
That’s the consensus EPS estimate for the quarter ended September 30, compared with C$0.21 a year earlier. Two analysts contributed to the C$0.24–C$0.27 estimate range. The consensus has fallen by one cent over the past 30 days.
Bull case
Dexterra’s recent results give investors a reason to look for continued growth. In the June quarter, the company reported EPS of C$0.20, above the C$0.18 estimate. Revenue and adjusted EBITDA also increased year over year, according to the supplied company release summary. For the September quarter, analysts expect revenue to grow 8.6% and EPS to rise 21.4% from a year earlier. Meeting or beating those estimates would suggest growth continued beyond the previous quarter. Over its last four comparable quarters, Dexterra beat EPS estimates twice, missed once and matched once.
Bear case
There are reasons for caution, too. Dexterra missed the EPS estimate in December 2025, and the latest consensus has fallen from C$0.27 to C$0.26 over the past month. All three recorded revisions were downward, with none upward. The forecast also draws on a small group of analysts, especially for EPS. Dexterra closed at C$19.07, near its 52-week high of C$19.27. That doesn’t predict how the stock will react, but a shortfall could draw attention. Investors should look beyond EPS to revenue and the company’s comments on operating performance.
Analysis
Dexterra is scheduled to report third-quarter 2026 results after the market closes on November 4. The company has scheduled a conference call for November 5, according to the supplied earnings-date notice. The main question is whether results for the quarter ended September 30 match analysts’ expectations of C$0.26 per share and C$305.52 million in revenue. Those estimates imply year-over-year growth of 21.4% in EPS and 8.6% in revenue. Two analysts contributed to the EPS consensus and four to the revenue estimate. With only two EPS estimates, the C$0.24–C$0.27 range is worth considering alongside the headline figure.
Analysis
Dexterra beat EPS estimates in two of its last four comparable quarters. It reported C$0.20 against an estimate of C$0.18 in June 2026, and C$0.19 against C$0.16 in March. Before those beats, it reported C$0.12 against C$0.18 in December 2025, then matched the C$0.21 estimate in September 2025. The supplied earnings table and chart show that results have not consistently topped expectations. The September-quarter consensus has also fallen from C$0.27 to C$0.26 over the past 30 days, with three downward revisions and none upward. The change is small, but C$0.26 is the current benchmark.
Analysis
Dexterra’s supplied Q2 results summary reported revenue of C$269.2 million, up from C$249.3 million a year earlier. Adjusted EBITDA grew 9.3%. Those results offer recent context, but the upcoming report will show whether that momentum continued through September.
At the latest supplied close of C$19.07, Dexterra had a market capitalization of about C$1.15 billion, a P/E ratio of 27.1 and a dividend yield of 2.24%. These figures describe the company’s current snapshot; they don’t predict how the stock will respond to earnings. The average analyst price target is C$19.94, or 4.5% above the supplied closing price. See the analyst ratings and targets for more context.
Wealth Awesome’s 90-day price forecast is based on a statistical model, not financial advice. It gives a mean estimate of C$22.80 and a 68% range of C$18.45 to C$28.18. Visit the DXT stock page for more company details.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
